Study guide
13.2 Local Anesthetic Systemic Toxicity (LAST) & 20% Lipid Emulsion Rescue Protocol
C-OBE Obstetric Emergencies Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Maternal Assessment, Risk Stratification & Early Warning Systems
1.1 Pre-Existing Medical, Surgical & Obstetric Comorbidities in Emergency Risk Stratification 1.2 Dynamic Antepartum & Intrapartum Risk Assessment 1.3 Maternal Early Warning Systems (MEWS/MEWT) & Critical Triage Physical Assessment 1.4 Alliance for Innovation on Maternal Health (AIM) Safety Bundles & Emergency Readiness
2 Chapter 2: Obstetric Hemorrhage — Etiology, Assessment & Uterotonics
2.1 Postpartum Hemorrhage Etiology (4 T's) & Quantitative Blood Loss (QBL) 2.2 Uterotonic Pharmacology & Stepwise Administration Protocols 2.3 Tranexamic Acid (TXA) Protocols & Hemorrhage Timing
3 Chapter 3: Obstetric Hemorrhage — Mechanical Interventions, Placental Disorders & Transfusion
3.1 Intrauterine Tamponade Balloons, Compression Sutures & Surgical Hemostasis 3.2 Ectopic Pregnancy, Placenta Previa, Accreta Spectrum (PAS), Abruption & Vasa Previa 3.3 Obstetric DIC, Coagulopathy & Massive Transfusion Protocol (MTP)
4 Chapter 4: Hypertensive Disorders of Pregnancy & Preeclampsia with Severe Features
4.1 Classification & Spectrum of Hypertensive Disorders of Pregnancy 4.2 Preeclampsia with Severe Features: Pathophysiology & End-Organ Damage 4.3 Diagnostic Evaluation, Laboratory Triggers & Fetal Surveillance in Preeclampsia
5 Chapter 5: Hypertensive Crisis, Eclampsia & Magnesium Sulfate Therapy
5.1 Acute Severe Hypertension & First-Line Antihypertensive Protocols 5.2 Eclampsia Recognition, Seizure Management & Airway Protection 5.3 Magnesium Sulfate Neuroprotection/Seizure Prophylaxis Protocols, Monitoring & Toxicity Reversal 5.4 HELLP Syndrome & Hepatic Crisis Management
6 Chapter 6: Maternal Resuscitation, Cardiac Arrest & Perimortem Cesarean
6.1 Maternal ACLS Modifications & Cardiopulmonary Resuscitation Physiology 6.2 Etiologies of Maternal Arrest & Structured Emergency Response 6.3 Perimortem Cesarean Delivery (PMCD / Resuscitative Hysterotomy)
7 Chapter 7: Amniotic Fluid Embolism & Maternal Shock States
7.1 Amniotic Fluid Embolism (AFE): Pathophysiology & Clinical Presentation 7.2 A-OK Protocol, Hemodynamic Support & Critical Care in AFE 7.3 Maternal Shock States: Hemorrhagic, Distributive, Cardiogenic & Obstructive
8 Chapter 8: Acute Intrapartum Delivery Emergencies
8.1 Shoulder Dystocia: Recognition, Timing & Primary HELPERR Sequence 8.2 Advanced Shoulder Dystocia Maneuvers & Neonatal Brachial Plexus Injury Prevention 8.3 Umbilical Cord Prolapse Recognition & Emergent Decompression Protocols
9 Chapter 9: Uterine Inversion, Malpresentation & Obstetric Trauma
9.1 Acute Uterine Inversion: Recognition, Tocolysis & Manual/Surgical Reduction 9.2 Emergency Vaginal Breech Extraction & Head Entrapment Maneuvers 9.3 Maternal Trauma: Primary/Secondary Survey, Placental Abruption & Fetomaternal Hemorrhage
10 Chapter 10: Maternal Sepsis, Intraamniotic Infection & Severe Infections
10.1 Maternal Sepsis: Physiological Criteria, S.O.S. Score & omSOFA 10.2 The Maternal Sepsis Hour-1 Bundle & Fluid/Vasopressor Optimization 10.3 Intraamniotic Infection (Triple I / Chorioamnionitis) & Severe Endometritis 10.4 Severe Pyelonephritis, Maternal Pneumonia & Severe Peripartum Infections
11 Chapter 11: Endocrine, Cardiovascular, Respiratory & Neurologic Emergencies
11.1 Diabetic Ketoacidosis (DKA), Maternal Hypoglycemia & Endocrine Resuscitation in Pregnancy 11.2 Peripartum Cardiomyopathy (PPCM), Acute Heart Failure, Acute Coronary Syndromes & Maternal Arrhythmias 11.3 Status Asthmaticus, Pulmonary Edema & ARDS in Pregnancy 11.4 Status Epilepticus, Acute Stroke & Cerebral Venous Sinus Thrombosis (CVST)
12 Chapter 12: Thromboembolism, Hepatorenal Disorders & Toxicologic Emergencies
12.1 Venous Thromboembolism (DVT/PE) Diagnosis, Treatment & Peripartum Anticoagulation 12.2 Acute Fatty Liver of Pregnancy (AFLP / Swansea Criteria) & Acute Kidney Injury 12.3 Peripartum Substance Overdose, Opioid Toxicity & Naloxone Administration
13 Chapter 13: Obstetric Anesthesia Emergencies & Critical Complications
13.1 High Spinal / Total Spinal Anesthesia & Aspiration Pneumonitis 13.2 Local Anesthetic Systemic Toxicity (LAST) & 20% Lipid Emulsion Rescue Protocol 13.3 Post-Dural Puncture Headache (PDPH), Epidural Hematoma & Abscess 13.4 Malignant Hyperthermia in Obstetric Anesthesia & Dantrolene Protocol
14 Chapter 14: Professional Practice, Team Communication, Debriefing & Health Equity
14.1 Crisis Resource Management (CRM), TeamSTEPPS & Structured Communication 14.2 Multidisciplinary Emergency Debriefing, Morbidity & Mortality, and Systems Learning 14.3 Perinatal Racial/Ethnic Disparities, Implicit Bias Mitigation & Respectful Maternity Care 14.4 Legal, Ethical, Documentation & EMTALA Standards in Obstetric Emergencies
13.2 Local Anesthetic Systemic Toxicity (LAST) & 20% Lipid Emulsion Rescue Protocol
Key Takeaways Explain This Topic AI
Local Anesthetic Systemic Toxicity (LAST) in obstetrics is primarily caused by accidental intravascular injection or rapid systemic absorption of amino-amide local anesthetics (especially Bupivacaine, Ropivacaine, and Lidocaine) into the engorged epidural venous plexus.
The classic presentation progresses from early CNS excitation (perioral numbness, metallic taste, tinnitus, lightheadedness, visual disturbances, tonic-clonic seizures) to CNS depression (coma, apnea) followed by severe cardiovascular toxicity (wide-complex arrhythmias, refractory ventricular fibrillation, profound myocardial depression, asystole).
20% Lipid Emulsion (Intralipid) is the definitive antidote, functioning via the 'lipid sink/sponge' scavenging mechanism, metabolic cardiotonic facilitation, and direct myocardial membrane ion channel reactivation; the dosing regimen is an immediate 1.5 mL/kg IV bolus over 2-3 minutes (~100 mL for a 70 kg adult), followed by a continuous infusion of 0.25 mL/kg/min (repeat bolus 1-2 times and double infusion to 0.5 mL/kg/min for refractory collapse; maximum cumulative dose 10-12 mL/kg over 30 minutes).
Standard ACLS must be strictly modified during LAST resuscitation: reduce individual Epinephrine boluses to <=1 mcg/kg (e.g., 10-100 mcg IV), avoid Vasopressin, avoid Calcium Channel Blockers and Beta-Blockers, and strictly avoid class 1b antiarrhythmics (Lidocaine) or other local anesthetics, using Amiodarone for ventricular arrhythmias.
Last updated: August 2026
Local Anesthetic Systemic Toxicity (LAST) & 20% Lipid Emulsion Rescue Protocol
Local Anesthetic Systemic Toxicity (LAST) is a life-threatening adverse reaction resulting from elevated systemic plasma concentrations of local anesthetics. In obstetric anesthesia, LAST most commonly occurs following inadvertent cannulation of an epidural vein during epidural catheter placement or top-up dosing, or following high-volume peripheral nerve blocks (such as transversus abdominis plane [TAP] or pudendal nerve blocks). Because of pregnancy-induced physiological adaptations, the parturient is uniquely susceptible to rapid cardiovascular collapse, making rapid recognition and execution of the ASRA/SOAP 20% Lipid Emulsion protocol essential.
1. Pathophysiology & Pharmacokinetics in Pregnancy
Local anesthetics block voltage-gated sodium channels ( I N a I_{Na} I N a ) along neural axons to inhibit depolarizing action potentials. When excessive concentrations reach systemic circulation, identical sodium channel blockade occurs in the central nervous system (CNS) and cardiac conduction system. +---------------------------------------------------------------------------------------------------+
- | LOCAL ANESTHETIC CLASSES & CARDIOTOXIC POTENTIAL |
- | |
- | • AMINO-AMIDES (Degraded by Hepatic Cytochrome P450 Enzymes): |
- | - Bupivacaine: Highest cardiotoxicity; high lipid solubility, strong protein binding (95%), |
- | slow receptor dissociation kinetics ("fast-in, slow-out"). |
- | - Levobupivacaine & Ropivacaine: Pure S-enantiomers; reduced cardiotoxicity compared to |
- | racemic bupivacaine, but severe toxicity can still occur at high doses. |
- | - Lidocaine: Intermediate potency; primarily neurotoxic at high levels; shorter duration. |
- | |
- | • AMINO-ESTERS (Hydrolyzed Rapidly by Plasma Pseudocholinesterase): |
- | - 2-Chloroprocaine: Ultra-rapid plasma half-life (~1-2 minutes); lowest risk of systemic |
- | toxicity; ideal for rapid surgical anesthesia in emergent cesarean delivery. |
- | - Tetracaine: Highly potent, long-acting; used predominantly in spinal anesthesia. |
- +---------------------------------------------------------------------------------------------------+
- Why the Obstetric Patient Is at Increased Risk for LAST
Venous Engorgement: Increased intra-abdominal pressure and inferior vena cava compression engorge the epidural venous plexus (Batson's plexus), substantially increasing the rate of accidental intravenous cannulation (up to 5-10% of epidural placements).
Reduced Alpha-1-Acid Glycoprotein (AAG): In pregnancy, plasma concentrations of AAG (the primary binding protein for local anesthetics) decrease by 30%, resulting in a dramatically higher free, active, unbound fraction of local anesthetic.
Progesterone-Enhanced Myocardial Sensitivity: High circulating levels of progesterone enhance the sensitivity of cardiac Purkinje fibers and myocytes to bupivacaine-induced sodium channel block.
Increased Cardiac Output & Regional Perfusion: Cardiac output increases 40-50%, accelerating systemic absorption from epidural, fascial, and subcutaneous tissue vascular beds.
2. Clinical Presentation: Biphasic Spectrum of LAST
The onset of toxicity may occur within seconds (direct intravascular injection) or be delayed for 15 to 45 minutes (gradual tissue absorption from continuous infusion or TAP block). +---------------------------------------------------------------------------------------------------+
- | PROGRESSION OF CLINICAL MANIFESTATIONS IN LAST |
- | |
- | 1. EARLY CNS EXCITATION (Loss of Inhibitory Cortical Pathways): |
- | • Numbness of tongue, perioral paresthesias, metallic taste in mouth. |
- | • Tinnitus, humming/buzzing sounds, auditory hallucinations. |
- | • Lightheadedness, dizziness, visual disturbances, blurred vision. |
- | • Restlessness, agitation, slurred speech, shivering, facial twitching, tremors. |
- | |
- | 2. CNS DEPRESSION & SEIZURES: |
- | • Generalized tonic-clonic seizures. |
- | • Sudden loss of consciousness, central apnea, coma. |
- | |
- | 3. INITIAL CARDIOVASCULAR RESPONSE (Sympathetic Stimulation): |
- | • Transient hypertension and tachycardia (due to central sympathetic discharge). |
- | |
- | 4. SEVERE CARDIOVASCULAR COLLAPSE (Direct Myocardial & Conduction Blockade): |
- | • Conduction Blocks: Prolonged PR interval, widened QRS complex, bundle branch blocks. |
- | • Ventricular Arrhythmias: Ventricular tachycardia (VT), Torsades de Pointes, Ventricular |
- | Fibrillation (VF) (characteristically refractory to standard defibrillation). |
- | • Severe Negative Inotropy: Profound hypotension, cardiogenic shock, electromechanical |
- | dissociation (PEA), and asystole. |
- +---------------------------------------------------------------------------------------------------+
Atypical Presentations: In up to 20-30% of LAST cases—especially with bupivacaine—cardiovascular collapse can occur suddenly without antecedent CNS prodromal symptoms or seizures.
The Epidural Test Dose Protocol
To detect intravascular catheter placement before injecting therapeutic doses, a test dose consisting of 3 mL of 1.5% Lidocaine with 1:200,000 Epinephrine (15 mcg Epinephrine) is administered.
Intravascular Injection Criteria: An increase in maternal heart rate >=10-20 bpm or an increase in systolic blood pressure >=15 mmHg within 60 seconds indicates intravascular injection.
Caution: Epinephrine test doses can yield false-positive responses during uterine contractions (which cause endogenous tachycardia) and false-negative responses in beta-blocked patients. Aspiration for blood before every injection is mandatory but has a 2% false-negative rate; always fractionate doses (e.g., 3-5 mL increments).
3. The 20% Lipid Emulsion (Intralipid) Rescue Protocol
Intravenous 20% Lipid Emulsion is the definitive pharmacological antidote for local anesthetic toxicity. Every obstetric unit must maintain a dedicated LAST Rescue Kit with clear dosing guidelines. +---------------------------------------------------------------------------------------------------+
- | MECHANISMS OF 20% LIPID EMULSION RESCUE |
- | |
- | 1. "LIPID SINK / LIPID SPONGE" EFFECT (Scavenging): |
- | • Creates a large intravascular lipid compartment that partitions and extracts lipophilic |
- | local anesthetic molecules away from target organs (heart and brain). |
- | |
- | 2. METABOLIC / ENERGETIC EFFECT: |
- | • Bupivacaine inhibits carnitine palmitoyl transferase-1 (CPT-1), blocking mitochondrial |
- | fatty acid oxidation. Lipid emulsion floods myocytes with fatty acid substrates, |
- | restoring ATP generation and cellular energetics. |
- | |
- | 3. DIRECT MEMBRANE / CARDIOTONIC EFFECT: |
- | • Activates voltage-gated calcium channels ($I_{Ca}$), promoting calcium influx and directly |
- | increasing myocardial contractility and stroke volume. |
- +---------------------------------------------------------------------------------------------------+
- Weight-Based Dosing Protocol (ASRA & SOAP Guidelines)
- Step Action Dosing for ~70 kg Adult Parturient
- 1. Initial Bolus Administer 20% Lipid Emulsion 1.5 mL/kg IV over 2 to 3 minutes ~100 mL IV bolus (rapid push)
- 2. Continuous Infusion Initiate continuous IV infusion at 0.25 mL/kg/min ~18 mL/min (~1,000 mL/hour)
3. Re-Bolus (if unstable) If cardiovascular instability persists or worsens, repeat bolus of 1.5 mL/kg every 3 to 5 minutes (up to 2 repeat boluses) 100 mL IV bolus (may repeat once or twice)
4. Increase Infusion (if unstable) Double infusion rate to 0.5 mL/kg/min if blood pressure remains low ~35 mL/min (~2,000 mL/hour)
5. Duration & Max Dose Continue infusion for at least 10 to 15 minutes after hemodynamic stability is restored. Maximum Upper Dose: 10 to 12 mL/kg over the first 30 minutes (approx. 700–800 mL)
4. ACLS Resuscitation Modifications for LAST
Standard Advanced Cardiovascular Life Support (ACLS) protocols must be fundamentally altered during LAST resuscitation. Failure to modify ACLS can worsen myocardial acidosis and render resuscitation ineffective. +---------------------------------------------------------------------------------------------------+
- | CRITICAL ACLS MODIFICATIONS IN LAST RESUSCITATION |
- | |
- | • REDUCE EPINEPHRINE DOSES TO <=1 mcg/kg: |
- | - Standard ACLS 1 mg Epinephrine boluses produce extreme peripheral vasoconstriction, severe |
- | arrhythmias, and myocardial lactate acidosis, which impairs lipid emulsion clearance. |
- | - Use **Epinephrine boluses of <=1 mcg/kg IV (e.g., 10 to 100 mcg IV boluses)** for shock. |
- | |
- | • STRICTLY AVOID VASOPRESSIN: |
- | - Vasopressin causes profound coronary vasoconstriction, pulmonary hemorrhage, and worse |
- | survival outcomes in local anesthetic-induced cardiac arrest. |
- | |
- | • STRICTLY AVOID CALCIUM CHANNEL BLOCKERS & BETA-BLOCKERS: |
- | - Worsens local anesthetic-induced negative inotropy, AV nodal blockade, and cardiogenic shock.|
- | |
- | • STRICTLY AVOID CLASS 1B ANTIARRHYTHMICS (LIDOCAINE, PROCAINAMIDE): |
- | - Administering lidocaine for bupivacaine-induced arrhythmias compounds local anesthetic |
- | levels and exacerbates toxicity. |
- | - **Preferred Antiarrhythmic: Amiodarone (150–300 mg IV)** is the drug of choice for |
- | ventricular arrhythmias. |
- | |
- | • SEIZURE MANAGEMENT: |
- | - First-line: **Benzodiazepines** (Midazolam 1–2 mg IV boluses). |
- | - Avoid Propofol in patients with hemodynamic compromise (Propofol is a myocardial depressant |
- | and its 10% lipid carrier is insufficient to serve as a lipid sink). |
- | |
- | • EXTRACORPOREAL LIFE SUPPORT (ECMO / CPB): |
- | - Alert the perfusion / ECMO team early if ROSC is not achieved rapidly. Cardiopulmonary |
- | bypass maintains organ perfusion until local anesthetic is cleared and metabolized. |
- +---------------------------------------------------------------------------------------------------+